XML 48 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements Of Cash Flows (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Cash flows from operating activities:    
Net earnings (loss) $ 128,109 $ 110,484
Adjustments to reconcile net earnings to net cash flows provided by operating activities:    
Depreciation and amortization 16,269 14,770
Net (gain) loss on sale of long-lived assets 0 599
Gain (loss) on deconsolidation (2,237) 0
Share-based compensation 3,966 3,412
Excess tax benefit from share-based compensation (1,210) (529)
Deferred income taxes 19,329 13,388
Equity in earnings of unconsolidated affiliates, net (1,098) (711)
Increase (decrease) in cash and cash equivalents, net of effects of acquisitions and dispositions, due to changes in:    
Accounts receivable, net (5,221) 2,935
Supplies inventory (320) 333
Prepaid and other current assets (2,057) (331)
Accounts payable (2,351) 901
Accrued expenses and other liabilities (2,155) (2,616)
Other, net 1,526 989
Net cash flows provided by operating activities 152,550 143,624
Cash flows from investing activities:    
Acquisition of interests in surgery centers and related transactions (18,346) (9,972)
Acquisition of property and equipment (12,472) (14,569)
Other 55 0
Net cash flows used in investing activities (30,763) (24,541)
Cash flows from financing activities:    
Proceeds from long-term borrowings 70,922 33,378
Repayment on long-term borrowings (96,222) (72,517)
Distributions to noncontrolling interests (91,526) (82,759)
Proceeds from issuance of common stock upon exercise of stock options 13,728 6,672
Repurchase of common stock (26,164) (7,219)
Capital contributions and ownership transactions by noncontrolling interests 936 1,519
Excess tax benefit from share-based compensation 1,210 529
Financing cost incurred (1,146) (1,755)
Net cash flows provided by (used in) financing activities (128,262) (122,152)
Net increase (decrease) in cash and cash equivalents (6,475) (3,069)
Cash and cash equivalents, beginning of period 46,398 40,718
Cash and cash equivalents, end of period $ 39,923 $ 37,649